• About
    • About Sutro
    • Leadership
      • Leadership Team
      • Functional Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Clinical Advisory Board
    • Collaborations
    • Corporate Presentation
  • Clinical Trials & CUA
    • Clinical Trials
    • Patient Resources
    • Commitment To Patients
    • Compassionate Use Access
  • Technology
    • iADCs & Antibody-Drug Conjugates
    • XpressCF+®
    • cGMP Facility
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Pipeline
  • News
    • News Releases
    • Clinical / Scientific Presentation & Publication Highlights
    • Events
    • Events Audio Replays
  • Careers and Culture
    • The Way We Work
    • Join Our Team
    • DEIB
      • DEIB Newsletter
    • Internships
    • Sutroites
    • Volunteer
      • Current Volunteer Newsletter
  • Contact Us

Sutro Biopharma to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

Events, News, Presentations, Press Releases

Sutro Biopharma to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference SOUTH SAN FRANCISCO, Calif., Jan. 6, 2022– Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company...

Virtual KOL Event: Discussion of STRO-002 Interim Dose Expansion Cohort Data – Presentation

Events, News, Presentations

Virtual KOL Event: Discussion of STRO-002 Interim Dose Expansion Cohort Data – Presentation Webcast, Jan 5, 2022 at 5:00pm EST...

Sutro Biopharma Announces Company KOL Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program STRO-002 for Treatment of Advanced Ovarian Cancer

Events, News, Presentations, Press Releases

Sutro Biopharma Announces Company KOL Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program STRO-002 for Treatment of Advanced Ovarian Cancer – Dr. Naumann and Sutro management to discuss interim data on the STRO-002 Phase 1...

Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China

News, Press Releases

Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China – Tasly obtains exclusive development and commercialization rights for STRO-002 for Greater China – – License includes a $40 million...

4th Annual Evercore ISI HeathCONx Conference – Presentation

Events, News, Presentations

4th Annual Evercore ISI HeathCONx Conference – Presentation Webcast, Nov 30, 2021 at 10:05am EST Download Presentation, Click...
« Older Entries

Sutro Biopharma

310 Utah Ave
Suite 150
South San Francisco, CA 94080
650.392.8412

Sutro Biopharma

111 Oyster Point Blvd
South San Francisco, CA 94080
Phone: 650-881-6500
Fax: 650-553-9659

Google Map

Tweets by @sutrobio

Contact Us

General Inquires: general@sutrobio.com
Business Inquires: busdev@sutrobio.com
Investor Relations Inquires: IR@sutrobio.com
Careers:
jobs@sutrobio.com

Copyright © 2022 Sutro Biopharma, Inc. South San Francisco, California, U.S.A.
Privacy Policy
  • Follow
  • Follow
  • Follow
Sign Up for Email Alerts